Pediatric cancer mortality and survival in the United States, 2001‐2016
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Although pediatric cancer mortality and survival have improved in the United States over the past 40 years, differences exist by age, race/ethnicity, cancer site, and economic status. To assess progress, this study examined recent mortality and survival data for individuals younger than 20 years. Methods: Age‐adjusted death rates were calculated with the National Vital Statistics System for 2002‐2016. Annual percent changes (APCs) and average annual percent changes (AAPCs) were calculated with joinpoint regression. Five‐year relative survival was calculated on the basis of National Program of Cancer Registries data for 2001‐2015. Death rates and survival were estimated overall and by sex, 5‐year age group, race/ethnicity, cancer type, and county‐based economic markers. Results: Death rates decreased during 2002‐2016 (AAPC, –1.5), with steeper declines during 2002‐2009 (APC, –2.6), and then plateaued (APC, –0.4). Leukemia and brain cancer were the most common causes of death from pediatric cancer, and brain cancer surpassed leukemia in 2011. Death rates decreased for leukemia and lymphoma but were unchanged for brain, bone, and soft‐tissue cancers. From 2001‐2007 to 2008‐2015, survival improved from 82.0% to 85.1%. Survival was highest in both periods among females, those aged 15 to 19 years, non‐Hispanic Whites, and those in counties in the top 25% by economic status. Survival improved for leukemias, lymphomas, and brain cancers but plateaued for bone and soft‐tissue cancers. Conclusions: Although overall death rates have decreased and survival has increased, differences persist by sex, age, race/ethnicity, cancer type, and economic status. Improvements in pediatric cancer outcomes may depend on improving therapies, access to care, and supportive and long‐term care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 1×
“4386 Cancer October 1, 2020 chimeric antigen receptor T therapy have shown effectiveness for pediatric ALL and may further improve survival for patients with pediatric ALL and reduce chemotherapy-related toxicity.(41,42) Improvements in lymphoma outcomes were seen during the study period, and they may be due to the im…”
BackgroundAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 1×
“Patients with neuroblastomas, who showed increased survival in this study over time, had improved outcomes in past studies in part because of advances in treatment such as the use of targeted antibody therapy.(5,47) The most common pediatric bone cancers (osteosarcomas and Ewing tumors) and soft-tissue sarcomas (rhabd…”
ResultOutcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
The Major Causes of Death in Children and Adolescents in the United States
Cunningham, R. M., Walton, M. A., & Carter, P. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmsr1804754 · Cited by 748 · cited 2×
“INTRODUCTION Cancer is the second leading cause of death after injury among people aged 1 to 19 years in the United States.(1) Five-year survival for patients with pediatric cancer improved from 63% in the 1970s to 83% in the 2000s.”
BackgroundDeclining childhood and adolescent cancer mortality
Smith, M. A., Altekruse, S. F., Adamson, P. C., Reaman, G. H., & Seibel, N. L. (2014) · Cancer · doi:10.1002/cncr.28748 · Cited by 542 · cited 8×
“The decrease in pediatric leukemia death rates over the past 40 years has been attributed to advances in treatment and supportive care, which have been driven by clinical research efforts.(2,5,37,38) Cooperative pediatric clinical trials have been instrumental in driving this improvement.”
BackgroundMethodResultInfluentialInterpreting trends in cancer patient survival
DICKMAN, P. W., & ADAMI, H. ‐. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01677.x · Cited by 508 · cited 1×
“Relative survival was calculated via the Ederer II method.(30,31) The cohort method was used to estimate survival for pediatric patients diagnosed in 2001-2007, and the complete method was used for patients diagnosed in 2012-2015 with less than 5 years of follow-up.”
MethodCD19 CAR T cell product and disease attributes predict leukemia remission durability
Finney, O. C., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., Futrell, B., Orentas, R. J., Li, D., Gardner, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125423 · Cited by 346 · cited 1×
“4386 Cancer October 1, 2020 chimeric antigen receptor T therapy have shown effectiveness for pediatric ALL and may further improve survival for patients with pediatric ALL and reduce chemotherapy-related toxicity.(41,42) Improvements in lymphoma outcomes were seen during the study period, and they may be due to the im…”
BackgroundAdolescent and young adult oncology—past, present, and future
Close, A. G., Dreyzin, A., Miller, K. D., Seynnaeve, B. K. N., & Rapkin, L. B. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21585 · Cited by 225 · cited 1×
“Because NPCR survival data cover 93% of the US population, it can provide a more comprehensive picture of pediatric cancer survival than past studies using the Surveillance, Epidemiology, and End Results database, that covered ≤28% of the US population at the time of these studies.(5,7)”
MethodMisclassification of race/ethnicity in a population-based cancer registry (United States)
Gomez, S. L., & Glaser, S. L. (2006) · Cancer Causes & Control · doi:10.1007/s10552-006-0013-y · Cited by 167 · cited 1×
“Finally, misclassification by race/ethnicity may occur, and rate numerators may underestimate Hispanics, American Indians, and Alaska Natives; this could artificially lower rates.(69) Life tables for Asians and Pacific Islanders may be less reliable than those of other races.”
BackgroundAbrahão, R., Lichtensztajn, D. Y., Ribeiro, R. C., Marina, N. M., Keogh, R. H., Marcos-Gragera, R., Glaser, S. L., & Keegan, T. H. M. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25544 · Cited by 89
Cited by
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B., & Rodriguez, A. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01380-x · Cited by 197
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60
Metadata
- Authors
- Siegel, D. A., Richardson, L. C., Henley, S. J., Wilson, R. J., Dowling, N. F., Weir, H. K., Tai, E. W., & Buchanan Lunsford, N.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2020-07-29
- Volume
- 126
- Issue
- 19
- Pages
- 4379-4389
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W3045710221
- Cited by
- 181
- References
- 10
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.